The effects of treatment with a somatostatin analog (Sandostatin, SMS201-995) were investigated in female rats with dimethylbenzanthracene(DMBA)-induced rat mammary tumors. A 3-week treatment was performed using sandostatin, the LHRH-agonist buserelin alone, or buserelin in combination with sandostatin. Twice daily sandostatin treatment was performed with dosages of 0.05/xg, 0.2/xg, 1/xg, 5/zg, and 20/zg. Buserelin was used in a 2 x 5 ~g/day dosage.
Introduction
Endocrine treatment of metastatic breast cancer is aimed at decreasing plasma concentrations of growth stimulatory hormones or factors, or at antagonizing the biological effects of these hormones and factors directly. The involvement of prolactin (PRL) and growth hormone (GH) in growth regulation of human breast cancer cells is still unclear, although numerous experimental data obtained with rodents support the contention that PRL is important in growth and development of their mammary tumors [e.g. [1] [2] [3] . The binding of human GH to the lactogenic receptor of human breast cancer cells in vitro and in vivo may also cause growth stimulatory effects [4] [5] [6] [7] . The observation of increased plasma levels of GH and PRL in breast cancer patients [8] may therefore be associated with a poorer prognosis compared to patients with low hormone levels, as described for GH in prostate cancer patients [9] .
Furthermore, GH can increase plasma levels and local production of insulin-like growth factor-1 (IGF-1 or somatomedin C) [10] [11] [12] [13] [14] . IGF-1 and estradiol (E2) are the most potent growth stimulatory agents for human breast cancer cells in vitro (for a review, see ref. 15 ). IGF-1 and epidermal growth factor (EGF) appear to be autocrine and paracrine growth factors for human breast cancer cells [15] . Recently, significant levels of IGF-1 receptors were demonstrated in more than 90% of human primary breast tumors [16] [17] [18] [19] . Therefore, inhibition of GH secretion (and possibly that of IGF-1 and EGF) by administration of somatostatin and its analogs may be a means for inhibiting breast cancer growth.
We found that somatostatin receptors are present in 15-19% of primary breast tumor specimens [19, 20] . Moreover, we have previously described the presence of somatostatin receptors in MCF-7 human breast cancer cells, and the growth inhibition of these cells caused by sandostatin [21] . The results from two first experiments with rat DMBAinduced mammary tumors suggested in vivo growth inhibition caused by sandostatin, besides additive inhibitory effects of sandostatin and the LHRH-agonist buserelin [22] . Combined treatment with buserelin and sandostatin was studied to find out whether the addition of sandostatin might improve the tumor remission observed after buserelin treatment alone [e.g. 23] .
Therefore, we have studied more extensively the possible direct and indirect (endocrine) growth inhibitory effects of chronic sandostatin treatment of female rats bearing mammary tumors, as a single agent or in combination with buserelin.
Materials and methods
Female rats of the Sprague-Dawley strain were obtained from the Zentralinstitut fur Versuchstierzucht, Hannover, F.R.G. Rats were kept four to a cage under controlled light conditions (light on: 8:00 AM; light off: 7:00 PM) on wood shavings and received standard dry pellets (Hope Farms, Woerden, The Netherlands) and tap water ad libitum.
Hormonal agent solutions
The somatostatin analog sandostatin (SMS201-995) was kindly supplied by Sandoz Ltd., Basel, Switzerland, in a stock solution of 0.1 mg/ml. The LHRH-agonist buserelin was kindly provided by Hoechst A.G., Frankfurt am Main, F.R.G., in a stock solution of lmg/ml. Work solutions were made by dilution of the stock solutions with 0.15 M NaC1. Twice-daily subcutaneous injections of sandostatin or buserelin solution were administered in a volume of 100/zl around 9:00AM and 5:00 PM. Control animals received daily injections of 100/zl saline. Final daily dosages per rat were: for sandostatin 2 x 0.05/zg, 2 x 0.2/xg, 2 x 1/zg, 2 x 5~g and 2 x 20/zg; for buserelin 2 x 5/zg (i.e. 40/zg/kg/day). The highest sandostatin dosage used was that described by Lamberts et al. [24] . In view of the desensitization reported by them, we decided to use lower sandostatin dosages to try to circumvent possible desensitization phenomena. Combined treatment with sandostatin and buserelin involved separate injections of either hormonal agent solution, at distant loci on the back of the rat.
Tumor induction
Dimethylbenzanthracene (DMBA, Fluka, Basel, Switzerland) was dissolved in olive oil at a concentration of 10mg/ml. The solution obtained was stored in the dark. Induction of mammary tumors was performed with 2 intragastric administrations of 1 ml of DMBA-solution given with a 7-day interval to 54--61 day old rats [25] .
Start of treatments
Animals were palpated twice weekly to detect the presence of mammary tumors. In total, six different experiments were performed. An overview of the experimental treatments as well as the number of rats used in the different treatment groups in the separate experiments is presented in Table 1 . It was impossible to collect data from all rats for each parameter for several reasons: untimely death of some rats, lack of enough tumor tissue after treatment, or insufficient amount of blood plasma. Treatment began when all rats had palpable tumors (105-115 days of age). In studying treatment effects on growth of these rat mammary tumors, we have found that some tumors may regress and some remain stable while other tumors progress, all on the same rat, and to some extent even in control rats. Therefore, we decided to use the total tumor load per rat to compare the treatment results on tumor growth. Rats were anaesthetized with diethyl ether, and the size of the individual tumors was measured with calipers and calculated as the product of the two largest perpendicular diameters. For each rat, the sum of the individual tumor areas was taken as the tumor load of the animal. Rats were divided between control and treatment groups (7-11 rats per group; equal numbers in the different groups in an individual experiment) in such a way that the same average tumor load was obtained in each group.
End of treatments
After treatment for 3 weeks, the tumor load was estimated again in anaesthetized rats. The next day, the last injections were given around 9:00 AM, and the animals were killed by decapitation without diethyl ether anaesthesia. Rats were killed one by one taking rats from the different treatment groups in succession. Blood was collected in heparinized tubes and in tubes with EDTA-solution. Plasma was stored at -20 ° C until assay for GH, PRL, luteinizing hormone (LH), follicle stimulating hormone (FSH), E2, insulin, and EGF-like activities. Tumor tissue was collected and stored at -70 ° C until assay for estrogen (ER) and progesterone receptor (PgR). Finally, the weights of the pituitary and adrenal glands, and of the ovaries, uterus, and pancreas, were recorded.
Steroid receptor and somatostatin receptor assays
Assay of cytosolic ER and PgR were performed by multiple-point Scatchard analysis, according to the procedures recommended by the EORTC for the measurement of ER and PgR in the cytosol of human breast tumor biopsies [26] . Somatostatin receptors were measured by autoradiography on 
Plasma hormone and growth factor assays
GH and PRL were assayed by radioimmunoassay [24] . Assays of LH and FSH were performed as described by Welschen et al. [30] . Results are expressed in terms of the standards LH RP-1 and FSH RP-1 from the NIAMD. E2 was assayed with kits obtained from Diagnostic Products Corporation, Los Angeles CA, USA. Assay of insulin was performed with a specific radioimmunoassay using a commercially available kit from Incstar, Stillwater, Minnesota, U.S.A. EGF-like activities were assayed by radioreceptor assay after acid-ethanol extraction of the plasma, using human placental membranes as receptor source [18] .
Statistical evaluation of results
The treatment effects of sandostatin and buserelin were analysed with ANOVA (analysis of variance) on the pooled data of the 6 experiments. In the ANOVA the experiment number was included as a nominal variable (6 levels) to correct for systematic differences between the experiments. For most of the endpoints statistically significant differences between experiments were found. This implied that inclusion of this factor in the ANOVA was required in order to obtain unbiased estimates of the treatment effects of sandostatin (nominal variable with 6 levels: 0/zg, 2 x 0.05/~g, 2 × 0.2/xg, 2 × 1/zg, 2 x 5/zg, 2 x 20/.~g) and buserelin (nominal variable with 2 levels: 0/zg, 2 x 5/zg). In case of a very skewed distribution of an endpoint, as was the case with most of the plasma hormone levels, alogarithmic transformation or a square root transformation was performed in order to obtain a more symmetrically distributed variable. The transformed variable was used in the ANOVA.
significant difference in tumor load between the groups treated with the different sandostatin dosages and control (ANOVA, P = 0.39). In contrast, the effect of buserelin treatment (average tumor remission of approx. 60%) was highly significant (P< 0.0001). Tumor remission after combined treatment with buserelin and three sandostatin dosages was not statistically different from that resulting from treatment with buserelin alone.
Effects on all other parameters

Results
Effects of treatments on tumor growth
The relative effects of chronic treatment with various dosages of sandostatin, with or without buserelin, on rat mammary tumor load are shown in Fig.  1 . Sandostatin treatment caused no inhibition of mammary tumor growth. There was no statistically ANOVA showed that treatment with buserelin (with or without sandostatin) had a strong and statistically highly significant effect on almost all of the endpoints studied ( Table 2) . No effect could be demonstrated on GH, EGF-like activities, or on the weights of the pituitary and the pancreas. Buserelin treatment resulted in a decrease in tumor load, ER, PgR, PRL, E2, and the weight of the ovaries and the uterus, besides an increase in LH, FSH, insulin, and the weight of the adrenals. Be- cause of these strong effects of buserelin, and as the majority of the animals were treated without buserelin, the effect of sandostatin was tested restricted to the animals treated without buserelin. For none of the endpoints (except for E2) was there a statistically significant difference between the 6 sandostatin treatment level groups (control included) (Table 2). The P-values in the table have not been corrected for multiple testing. The sandostatin effect on E2 might be due merely to chance fluctuation, in view of the fact that a test for trend was not significant, i.e. there was no evidence for a monotonic relation between the dosage of sandostatin and the mean value of E2.
Somatostatin receptors
No receptors for somatostatin could be demonstrated in any of 7 tumors investigated (Fig. 2) .
Discussion
In contrast to our preliminary observations of inhibitory effects of sandostatin treatment on growth of DMBA-induced rat mammary tumors I22], the present results obtained in a more elaborate in vivo study in female rats showed that sandostatin treatment did not result in growth inhibition of these mammary tumors. For most of the endpoints investigated statistically significant differences between the six experiments were found, but after inclusion of the experiment number to correct for systematic differences between the experiments, no significant effects on tumor growth were determined. The absence of somatostatin receptors in this tumor model makes it unlikely for direct growth inhibitory effects to occur. This is in contrast to our observations of inhibitory effects of somatostatin analogs on growth of MCF-7 breast cancer cells, which do contain somatostatin receptors [21] . Furthermore, chronic treatment with the different sandostatin dosages was unable to suppress plasma levels of hormones and growth factors of interest, i.e. GH, PRL, insulin, and EGF-like activities.
This phenomenon might be explained by the development of pituitary desensitization by down-regulation of pituitary somatostatin receptors [24] , or by missing short-term endocrine effects, since all animals received their last injections early in the morning whereas actual killing of these animals occurred during the day.
It is difficult to explain the significant decrease in plasma E2 levels. This might be due to chance fluctuation, in view of the absence of a monotonic relation between the dosages of sandostatin and the mean values of E2, and because of the absence of a significant effect on uterus weight. On the other hand, somatostatin has been reported to inhibit gonadotropin secretion in response to administration of LHRH in normal men [31] and menstruating women [32] . A dissociation between the effects on LHRH-induced LH and FSH secretion was observed, showing only a significantly decreased LH secretion [32] . Furthermore, Schally and Redding [33] reported significantly (p = 0.05) decreased testes weights and plasma testosterone levels in rats with Dunning prostate tumors treated with microcapsules containing the somatostatin analog RC-160. These effects on pituitary-gonadal function by somatostatin (analogs) might be explained by effects at the level of the hypothalamus involving catecholamine secretion [32] , and/or by direct effects on the gonads [33] .
Our results are not in agreement with those reported by other investigators using other experimental mammary tumor models [12, 13, 34, 35] . Administration of a somatostatin analog has resulted in regression of nitrosomethylurea-induced rat mammary carcinoma [34] , as well as regression of both MT/W9A rat mammary adenocarcinomas [13] and MXT mouse mammary carcinomas [35] . The different results obtained may be due to: 1. the different tumor models used; 2. differences in numbers of animals investigated; 3. the presence or absence of somatostatin receptors; 4. the different somatostatin analogs used [36] ; 5. differences in dosages; 6. different modes of administration. Treatment with somatostatin analogs may cause different endocrine effects in the various models. As in our present study, the number of animals and experiments used might influence definite conclusions. Of paramount importance might be the presence of somatostatin receptors required for direct growth inhibitory effects. Schally's group demonstrated somatostatin receptors in MXT mouse mammary carcinoma [35] , while we could not demonstrate these receptors in the DMBA-induced mammary tumors. In their experiments, the microcapsules containing the somatostatin analog RC-160 liberated 25/xg per day, a dose not different from the highest sandostatin dose in the present study. In a transplantable pancreatic tumor model we observed no difference in antitumor efficacy of equal dosages of RC-160 and sandostatin, with both drugs administered by daily injections [37] . Therefore, besides the presence of somatostatin receptors in their tumor model, the better results reported by Szende et al. [35] might also be explained by the mode of drug administration (microcapsules vs. daily injections). Continuous administration of hormone analogs by implants [23] or microcapsule formulations [35] proved to be more effective than daily injections, as also concluded by Szende et al. [35] . In fact, with respect to LHRH analogs, we found increased plasma gonadotropin levels after treatment with buserelin injections, whereas decreased levels were caused by implants [23] . Also, a delayed release formulation of the somatostatin analog RC-160 appeared more inhibitory towards PRL secretion than i.v. injection of the drug [38] .
Regarding human breast cancers, direct growth inhibitory effects of somatostatin analogs are possible in view of the presence of somatostatin receptors in one-sixth up to one-half of tumor samples. In continuation of our initial report [39] , we have found somatostatin receptors in 15% of 110 human primary breast tumors by autoradiography [19] . This percentage is higher, when fresh and larger tumor specimens are used [40] . Papotti et al. [41] demonstrated somatostatin receptors in 17% of 100 breast tumors, and observed a significant relationship with expression of neuroendocrine markers. Fekete et al. [42] found somatostatin receptors in even 36% of 178 biopsy samples by biochemical methods. In our experience, patients with somatostatin receptor-positive breast tumors have a better prognosis than patients with somatostatin recep-tor-negative tumors [19] . Antitumor effects of sandostatin treatment on growth of human breast cancer cells have been demonstrated in vitro [21] and in nude mice [43] . In patients with metastatic breast cancer significant endocrine effects have been demonstrated due to chronic sandostatin treatment, suggesting also the possibility of indirect endocrine inhibition of tumor growth [44, 45, 46] . However, thus far, the antitumor effects in these two phase II studies were disappointing. Manni et al. [44, 45] observed a tumor response in only 1 out of 10 patients, whereas Vennin et al. [46] observed stable disease for longer than three months in only 3 out of 14 evaluable patients. These relatively poor results might be explained by the fact that all patients were heavily pretreated and that other growth stimulatory hormones were not antagonized. Therefore, for more definite conclusions on the value of somatostatin analog traeatment in breast cancer we need more (randomized) trials.
